We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Tools Designed to Study Genomic Instability

By LabMedica International staff writers
Posted on 01 Jul 2010
Print article
A new second-generation poly-adenylyltransferase [ADP]-ribose polymerase (PARP) in vivo pharmacodynamic assay that accurately measures net poly(ADP-ribose) (PAR) levels in cellular extracts, is being used to document differences in PAR levels in human tumor lysates from a variety of tissues, organs, and xenografts.

PARP is a protein involved in a number of cellular processes including catalyzing the nicotinamide adenine dinucleotide (NAD)-dependent addition of PAR onto itself and other adjacent nuclear proteins. PARP-1 is widely regarded as a promising target for the development of drugs useful in various regimes of cancer therapy, inflammation, ischemia, and neurodegeneration. More recently, the discovery that breast cancers deficient in homologous recombination are sensitive to nontoxic PARP inhibitors has resulted in efforts by numerous pharmaceutical companies to develop PARP-1 specific drugs.

Amsbio's (Abingdon, UK) PARP in vivo pharmacodynamic assay uses a validated sample processing regime and a chemiluminescent, sandwich enzyme-linked immunosorbent assay (ELISA) format, with precoated 96-stripwell plates. The assay reports PAR level with high signal to noise ratio; sensitivity of 2 pg/mL and a linear dynamic range to 1,000 pg/mL. Consequently, the PARP in vivo pharmacodynamic assay offers an exciting new application that provides evidence of drug action on molecular targets and generates baseline values that may be used to stratify patient response to therapy.

AMS Biotechnology (Amsbio) is an international provider of products and services for life sciences research. The Amsbio range includes over 23,000 polyclonal and monoclonal antibodies, peptides, recombinant proteins, extracellular matrix, molecular detection reagents, tissue DNA, RNA, protein and microarray products. Key research areas include apoptosis, cell invasion and migration, cell signaling, DNA damage, electrophoresis, glycobiology, posttranslational modification, and stem cell biology.

Related Links:
Amsbio


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Rubella Infection ELISA
ReQuest RUBELLA IgM ELISA Kit
New
Serum Toxicology Benzodiazepine Assay
DRI Serum Toxicology Benzodiazepine Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The artificial intelligence models can personalize immune therapies in oncology patients (Photo courtesy of 123RF)

AI Tool Identifies Novel Genetic Signatures to Personalize Cancer Therapies

Lung cancer and bladder cancer are among the most commonly diagnosed cancers globally. Researchers have now developed artificial intelligence (AI) models designed to personalize immune therapies for oncology... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.